WO1992017151A3 - Procede d'administration de medicaments par l'intermediaire de la modification des jonctions occlusives eptheliales par le facteur de necrose tumorale - Google Patents

Procede d'administration de medicaments par l'intermediaire de la modification des jonctions occlusives eptheliales par le facteur de necrose tumorale Download PDF

Info

Publication number
WO1992017151A3
WO1992017151A3 PCT/US1992/002312 US9202312W WO9217151A3 WO 1992017151 A3 WO1992017151 A3 WO 1992017151A3 US 9202312 W US9202312 W US 9202312W WO 9217151 A3 WO9217151 A3 WO 9217151A3
Authority
WO
WIPO (PCT)
Prior art keywords
necrosis factor
tumor necrosis
administering
pharmacologically
homeostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/002312
Other languages
English (en)
Other versions
WO1992017151A2 (fr
Inventor
James M Mullin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lankenau Institute for Medical Research
Original Assignee
Lankenau Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lankenau Institute for Medical Research filed Critical Lankenau Institute for Medical Research
Publication of WO1992017151A2 publication Critical patent/WO1992017151A2/fr
Publication of WO1992017151A3 publication Critical patent/WO1992017151A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Procédé et système d'administration trans-épithéliale de substances pharmacologiquement actives à travers les barrières épithéliales mammifères. Ils comportent l'administration séquentielle à des cellules épithéliales prédéterminées comprises dans la barrière de cellules épithéliales mammifères, portant des récepteurs du facteur de nécrose tumorale et présentant entre elles une résistance homéostatique de jonction occlusive, d'une quantité suffisante d'une substance biologiquement active apte à entrer en réaction avec lesdits récepteurs du facteur de nécrose tumorale, pour réduire ladite résistance homéostatique de jonction occlusive et pour permettre ainsi le passage trans-épithélial desdites substances pharmacologiquement actives à travers lesdites barrières; puis l'administration exogène d'une substance pharmacologiquement active dans un vecteur pharmaceutiquement acceptable à une barrière épithéliale mammifère prédéterminée avant que ladite résistance de jonction occlusive ne retourne audit état homéostatique.
PCT/US1992/002312 1991-03-27 1992-03-20 Procede d'administration de medicaments par l'intermediaire de la modification des jonctions occlusives eptheliales par le facteur de necrose tumorale Ceased WO1992017151A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67575491A 1991-03-27 1991-03-27
US675,754 1991-03-27

Publications (2)

Publication Number Publication Date
WO1992017151A2 WO1992017151A2 (fr) 1992-10-15
WO1992017151A3 true WO1992017151A3 (fr) 1992-11-12

Family

ID=24711843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002312 Ceased WO1992017151A2 (fr) 1991-03-27 1992-03-20 Procede d'administration de medicaments par l'intermediaire de la modification des jonctions occlusives eptheliales par le facteur de necrose tumorale

Country Status (2)

Country Link
AU (1) AU1768692A (fr)
WO (1) WO1992017151A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004663A1 (fr) * 1987-11-18 1989-06-01 State Of Oregon Acting By And Through The State Bo Procede d'administration de matiere genetique a travers la barriere sanguine du cerveau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004663A1 (fr) * 1987-11-18 1989-06-01 State Of Oregon Acting By And Through The State Bo Procede d'administration de matiere genetique a travers la barriere sanguine du cerveau

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cancer Research, vol. 50, no. 7, 1 April 1990, J.M. MULLIN et al.: "Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability", pages 2172-2176, see the whole document *
FEBS Letters, vol. 221, no. 2, 14 September 1987, J.M. MULLIN et al.: "The phorbol ester, TPA, increases transepithelial epidermal growth factor flux", pages 359-364, see the whole document *
J. Cell. Biology, vol. 115 (3 part 2), 1991, A.D. MARMORSTEIN et al.: "Tumor necrosis factor but not interleukin-1 increases the permaebility of a renal epithelium (MDCK)", page 480A, see the whole document *
The Journal of Cell Biology, vol. 109, no. 4, October 1989, J.M. MULLIN et al.: "Tumor necrosis factor causes leakiness in epithelial tight junctions", see the whole document *

Also Published As

Publication number Publication date
AU1768692A (en) 1992-11-02
WO1992017151A2 (fr) 1992-10-15

Similar Documents

Publication Publication Date Title
OPPENHEIMER et al. Effect of prednisone on thyroxine-binding proteins
Maltoni et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients
FI963533A7 (fi) Menetelmä ja väline tiettyjen kohdesolujen havaitsemiseksi erilaistuneissa tai solusekapolulaatioissa ja liuoksia, jotka sisältävät solusekapopulaatioita
FI873948L (fi) Menetelmä ihmisen kasvainkuoliotekijän (TNF) kanssa reagoivan monoklonaalisen vasta-aineen valmistamiseksi ja vasta-ainetta tuottava hybridisolulinja
HUP0301102A3 (en) Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
CA2216437A1 (fr) Composition pharmaceutique contenant des hydrates de carbonate de lanthane selectionnes
FI951161L (fi) Parannettu menetelmä spesifisten kohdesolujen havaitsemiseksi erikoistuneessa tai solusekapopulaatiossa ja solusekapopulaatioita sisältävissä liuoksissa
EP0415733A3 (en) Fuel cell fluid flow field plate
WO1992017151A3 (fr) Procede d'administration de medicaments par l'intermediaire de la modification des jonctions occlusives eptheliales par le facteur de necrose tumorale
Key et al. Assessment of cell proliferation by means of an enzyme-linked immunosorbent assay based on the detection of the Ki-67 protein
ES2016033A6 (es) Procedimiento de obtencion de una nueva forma farmaceutica de libeeracion prolongada basada en un complejo resina-principio activo.
Jeschke et al. The effect of hepatocyte growth factor on gut mucosal apoptosis and proliferation, and cellular mediators after severe trauma
CA2059060A1 (fr) Complementation des recepteurs de surface de cellules
Scatina et al. Etodolac kinetics in the elderly
AU3221793A (en) Factor x-derived polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting inflammation
Takaishi et al. Auranofin, an oral chrysotherapeutic agent, inhibits histamine release from human basophils
Glencross et al. Monoclonal antibody enhancement of FSH-induced uterine growth in snell dwarf mice
Cremer et al. Calciuric response to 1, 25-(OH) 2D3 in early renal failure
EP2039368A3 (fr) Procédé pour empêcher la réactivation d'un virus latent et contrôler la réplication du virus
Newton et al. Lorazepam solubility in and sorption from intravenous admixture solutions
Wang et al. Inhibition of granulocyte colony stimulating factor (G-CSF) adsorption to polyvinyl chloride using a nonionic surfactant
Uemasu et al. Effects of low dose of recombinant human growth hormone on renal excretion of insulin-like growth factor-I (IGF-I) in humans: an inverse relation between serum and urinary IGF-I level
IT8648693A0 (it) Sistema di protezione interna per serbatoi,in particolare serbatoi in terrati per combustibili e simili
Boado et al. Triiodothyronine metabolism in diabetic rats
Kadmenskij To the mechanism of atypically high energy losses and multiple scattering in crystal

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

COP Corrected version of pamphlet

Free format text: PAGES 1-18,DESCRIPTION,PAGES 19-21,CLAIMS,AND PAGES 1/8-8/8,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA